Lexaria Bioscience Corp. (LEXX) Form 424B3 — Oct 13, 2026
Lexaria Bioscience filed a 424B3 prospectus registering the resale of up to 923,827 shares of common stock issuable upon exercise of Series A, Series B, and placement agent warrants issued in connection with its September 2026 warrant inducement. The company will receive no proceeds from selling stockholder sales; potential proceeds come only from future cash warrant exercises, totaling up to approximately $11.76 million at a $12.67 exercise price versus a stock price of $3.20 as of October 12, 2026. The registration adds meaningful dilution overhang: 923,827 potential new shares against 2,106,528 shares outstanding — roughly a 30% increase if all warrants are exercised and sold.
Key figures
- Shares Offered
- 923827
- Shares Outstanding
- 2106528
- Last Reported Price
- $3.20 (Oct 12, 2026)
- Reverse Split Ratio
- 1-for-15 (effective Aug 3, 2026)
- Inducement Exercise Price
- $12.92
- Inducement Gross Proceeds
- $5.9 million
- Series AWarrant Exercise Price
- $12.67
- Series BWarrant Exercise Price
- $12.67
- Shares Outstanding After Offering
- 3030355
- Potential Warrant Exercise Proceeds
- $11,760,182
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.